The number of new cancer diagnoses in the United States is estimated to be 1,665,540 (excluding basal-cell and squamous-cell skin cancers) in 2014. The study of tumor biology in drug development and as a guide for selecting therapy for the individual patient has translated into improved outcomes for many patients with cancer.
Angiogenesis, the development of new blood vessels from preexisting vessels, is considered to be one of the central “hallmarks” in most malignancies.
The Multinational Association of Supportive Care in Cancer, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network (NCCN) each publish antiemetic and supportive care guidelines for patients who are undergoing chemotherapy treatment.
The effects of CIPN are generally symmetrical, distal, in a stocking-glove distribution, and primarily affect the upper and lower extremities. These are usually sensory effects (burning, freezing, electroshock-like); however, there are more agent-specific neuropathies, such as constipation seen with vincristine; orthostasis with bortezomib; or temperature-related effects with oxaliplatin.
First Anti–PD-1 Immunotherapy, Pembrolizumab, Receives Accelerated FDA Approval for Advanced Melanoma;
Ibrutinib Received Expanded Indication for Patients with CLL and 17p Deletion;
FDA Approved Idelalisib for Three Types of Hematologic Cancers;
Belinostat Approved for Peripheral T-Cell Lymphoma, an Aggressive Form of NHL;
Lymphoseek Injection Received Expanded Indication for Head and Neck Cancer SLN Biopsy

Results 1 - 6 of 6